Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Nyström Lennarth 1944 ) > Recommendations fro...

Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative

Giorgi Rossi, Paolo (författare): Azienda Unità Sanitaria Locale—IRCCS di Reggio Emilia, Reggio Emilia, Italy

Lebeau, Annette (författare): Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Canelo-Aybar, Carlos (författare): Iberoamerican Cochrane Center, Biomedical Research Institute (IIB Sant Pau-CIBERESP), Barcelona, Spain; Department of Paediatrics, Obstetrics and Gynaecology, Preventive Medicine, and Public Health, PhD Programme in Methodology of Biomedical Research and Public Health, Universitat Autònoma de Barcelona, Bellaterra, Spain

visa fler...

Saz-Parkinson, Zuleika (författare): European Commission, Joint Research Centre (JRC), Ispra, Italy; Instituto de Salud Carlos III, Health Technology Assessment Agency, Avenida Monforte de Lemos 5, Madrid, Spain

Quinn, Cecily (författare): St. Vincent’s University Hospital, Dublin, Ireland

Langendam, Miranda (författare): Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health Institute, Amsterdam, Netherlands

Mcgarrigle, Helen (författare): Cardiff and Vale UHB - General Surgery, Cardiff, United Kingdom

Warman, Sue (författare): Havyatt Lodge, Havyatt Road, North Somerset, Langford, United Kingdom

Rigau, David (författare): Iberoamerican Cochrane Center, Biomedical Research Institute (IIB Sant Pau-CIBERESP), Barcelona, Spain

Alonso-Coello, Pablo (författare): Iberoamerican Cochrane Center, Biomedical Research Institute (IIB Sant Pau-CIBERESP), Barcelona, Spain

Broeders, Mireille (författare): Department for Health Evidence, Radboud University Medical Center, Nijmegen, Netherlands; Dutch Expert Centre for Screening, Nijmegen, Netherlands

Graewingholt, Axel (författare): Radiologie am Theater, NRW, Paderborn, Germany

Posso, Margarita (författare): Iberoamerican Cochrane Center, Biomedical Research Institute (IIB Sant Pau-CIBERESP), Barcelona, Spain; Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain

Duffy, Stephen (författare): Centre for Cancer Prevention, Queen Mary University of London, Charterhouse Square, London, United Kingdom

Schünemann, Holger J. (författare): Michael G. DeGroote Cochrane Canada and McGRADE Centres; Department of Health Research Methods, Evidence and Impact, McMaster University Health Sciences Centre, ON, Hamilton, Canada

Autelitano, Mariangela (författare): Cancer Registry of Milan, Milan, Italy

Borisch, Bettina (författare): Institute of Global Health. University of Geneva, Geneva, Switzerland

Castells, Xavier (författare): IMIM, Barcelona, Spain

Colzani, Edoardo (författare): European Centre for Disease Control and prevention (ECDC), Solna, Sweden

Daneš, Jan (författare): Charles University in Prague, Prague, Czech Republic

Fitzpatrick, Patricia (författare): National Screening Service, Dublin, Ireland

Giordano, Livia (författare): CPO-Piedmont - AOU Citta` della Salute e della Scienza, Torino, Italy

Hofvind, Solveig (författare): Cancer Registry of Norway, Oslo, Norway

Ioannidou-Mouzaka, Lydia (författare): University of Athens Medical School, Athens, Greece

Knox, Susan (författare): Europa Donna, Milan, Italy

Nyström, Lennarth, 1944- (författare): Umeå universitet,Institutionen för epidemiologi och global hälsa

Parmelli, Elena (författare): European Commission, Joint Research Centre, Ispra, Italy

Perez, Elsa (författare): University Hospital Dr. Josep Trueta, Girona, Spain

Torresin, Alberto (författare): Ospedale Niguarda Ca’ Granda, Milan, Italy

Van Engen, Ruben (författare): Dutch Reference Centre for Screening, Nijmegen, Netherlands

Van Landsveld-Verhoeven, Cary (författare): Dutch Reference Centre for Screening, Nijmegen, Netherlands

Young, Ken (författare): National Coordinating Centre for the Physics of Mammography, Guildford, United Kingdom

visa färre...

(creator_code:org_t)

2021-02-18
2021
Engelska.
Ingår i: British Journal of Cancer. - : Springer. - 0007-0920 .- 1532-1827. ; 124:9, s. 1503-1512

Relaterad länk:: https://doi.org/10.1...; visa fler...; https://umu.diva-por... (primary) (Raw object); https://www.nature.c...; https://urn.kb.se/re...; https://doi.org/10.1...; visa färre...

Forskningsöversikt (refereegranskat)

Abstract Ämnesord

Stäng

Background: Predicting the risk of recurrence and response to chemotherapy in women with early breast cancer is crucial to optimise adjuvant treatment. Despite the common practice of using multigene tests to predict recurrence, existing recommendations are inconsistent. Our aim was to formulate healthcare recommendations for the question “Should multigene tests be used in women who have early invasive breast cancer, hormone receptor-positive, HER2-negative, to guide the use of adjuvant chemotherapy?”Methods: The European Commission Initiative on Breast Cancer (ECIBC) Guidelines Development Group (GDG), a multidisciplinary guideline panel including experts and three patients, developed recommendations informed by systematic reviews of the evidence. Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to Decision frameworks were used. Four multigene tests were evaluated: the 21-gene recurrence score (21-RS), the 70-gene signature (70-GS), the PAM50 risk of recurrence score (PAM50-RORS), and the 12-gene molecular score (12-MS).Results: Five studies (2 marker-based design RCTs, two treatment interaction design RCTs and 1 pooled individual data analysis from observational studies) were included; no eligible studies on PAM50-RORS or 12-MS were identified and the GDG did not formulate recommendations for these tests.Conclusions: The ECIBC GDG suggests the use of the 21-RS for lymph node-negative women (conditional recommendation, very low certainty of evidence), recognising that benefits are probably larger in women at high risk of recurrence based on clinical characteristics. The ECIBC GDG suggests the use of the 70-GS for women at high clinical risk (conditional recommendation, low certainty of evidence), and recommends not using 70-GS in women at low clinical risk (strong recommendation, low certainty of evidence).

Hitta via bibliotek

British Journal of Cancer (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: British Journal ...

Av lärosätet: Umeå universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se

Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative

Ämnesord

Publikations- och innehållstyp

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Sök utanför SwePub